Background Pulmonary fibrosis is one of the sequelae of the COVID-19, which seriously
affects the quality of life of survivors. Currently, there are no optimal evidence based …

Background Patients with idiopathic pulmonary fibrosis (IPF) frequently have multiple
comorbidities, which may influence survival but go under-recognised in clinical practice. We …

Idiopathic pulmonary fibrosis (IPF), the most common form of fibrosing idiopathic interstitial
pneumonia, is an inexorably progressive disease with a 5-year survival of~ 20%. In the last …

Rationale: Patients with fibrotic interstitial lung disease often progress to the point of
requiring supplemental oxygen. This is invariably accompanied by an impaired quality of life …

Aging and smoking are associated with the progressive development of three main
pulmonary diseases: chronic obstructive pulmonary disease (COPD), interstitial lung …

Transforming growth factor-β (TGF-β) is a member of a superfamily of pleiotropic proteins
that regulate multiple cellular processes such as growth, development and differentiation …

Myocardial fibrosis is recognized as a key pathological process in the development of
cardiac disease and a target for future therapeutics. Despite this recognition, the assessment …

Progressive fibrosing interstitial lung disease (PF-ILD) describes a phenotypic subset of
interstitial lung diseases characterized by progressive, intractable lung fibrosis. PF-ILD is …

Fibrosis-related disorders account for an enormous burden of disease-associated morbidity
and mortality worldwide. Fibrosis is defined by excessive extracellular matrix deposition at …

Background A number of circulating plasma biomarkers have been shown to predict survival
in patients with idiopathic pulmonary fibrosis (IPF), but most were identified before the use of …